TECHBIO-TECHNE Corp
Biological Products, (no Diagnostic Substances)
- Revenue
- $1.2B
- 0.4% YoY
- Operating margin
- 20.7%
- 147% YoY
- EBITDA
- $349M
- 65% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.2×
- −$65M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear398% of net incomeCash flow under 80% of net income
- Dilutive SBCClear3% of revenueOver 10% of revenue
- Payouts exceed cash flowClear31% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear38% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B | 0.4% |
| Operating income | $297M | $299M | $207M | $102M | $252M | 146% |
| Net income | $272M | $285M | $168M | $73M | — | |
| Operating cash flow | $325M | $254M | $299M | $288M | $292M | 1.6% |
| Capex | $45M | $38M | $63M | $31M | $29M | 7.0% |
| Stock-based comp | $42M | $39M | $38M | $41M | $41M | 1.3% |
| Buybacks | $161M | $20M | $80M | $276M | $42M | 85% |
| Dividends | $50M | $50M | $50M | $50M | $50M | 0.9% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.